Table 1.
Gender, age, treatment, and diagnosis of children presented as numbers (%)
| Cryotherapy n = 26 (%) | Control n = 23 (%) | Total n = 49 (%) | |
|---|---|---|---|
| Gender | |||
| Male | 15 (57.7) | 11 (47.8) | 26 (53.1) |
| Female | 11 (42.3) | 12 (52.2) | 23 (46.9) |
| Age group | |||
| < 7 years | 4 (15.4) | 7 (30.4) | 11 (22.4) |
| ≥ 7 years | 22 (84.6) | 16 (69.6) | 38 (77.6) |
| HSCT | |||
| Allogeneic RD | 10 (38.5) | 6 (26.1) | 16 (32.6) |
| Allogeneic URD | 11 (42.3) | 13 (56.5) | 24 (49.0) |
| Autologous | 5 (19.2) | 4 (17.4) | 9 (18.4) |
| Diagnosis | |||
| ALL | 10 (38.5) | 5 (21.7) | 15 (30.6) |
| AML | 2 (7.7) | 2 (8.7) | 4 (8.2) |
| CML | 0 (0) | 2 (8.7) | 2 (4.1) |
| Lymphoma | 3 (11.5) | 3 (13.0) | 6 (12.2) |
| Neuroblastoma | 1 (3.8) | 2 (8.7) | 3 (6.1) |
| Ewing sarcoma | 1 (3.8) | 0 (0) | 1 (2.0) |
| MDS | 2 (7.7) | 2 (8.7) | 4 (8.2) |
| HLH | 0 (0) | 1 (4.3) | 1 (2.0) |
| SAA | 1 (3.8) | 0 (0) | 1 (2.0) |
| Fanconi anemia | 2 (7.7) | 2 (8.7) | 4 (8.2) |
| Thalassemia | 2 (7.7) | 2 (8.7) | 4 (8.2) |
| Sickle cell disease | 1 (3.8) | 1 (4.3) | 2 (4.1) |
| MS | 1 (3.8) | 1 (4.3) | 2 (4.1) |
RD related donor, URD unrelated donor, ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, CML chronic myeloid leukemia, MDS myelodysplastic syndrome, HLH hemophagocytic lymphohistiocytosis, SAA severe aplastic anemia, MS multiple sclerosis